cryptocurrency is digital currency, People also ask

The total investment scale of Haiyouwei's factory in the United States may reach 10 million US dollars. According to Haiyouwei Science and Technology, on December 11th, Haiyouwei announced that it planned to set up a subsidiary in the United States to implement the polymer special membrane project. This project is a deepening cooperation between Haiyouwei and its industry partners on the basis of strategic and technical cooperation in the United States. It is an important measure to achieve the localized production and market-oriented extension of the company's photovoltaic packaging film in the American market. It is estimated that the total investment will not exceed 10 million US dollars.The Chinese medicine sector collectively pulled up Panlong Pharmaceutical's linear daily limit, Panlong Pharmaceutical's linear daily limit, Xiangxue Pharmaceutical, Kunyao Group, Huasen Pharmaceutical, Jingxin Pharmaceutical, Xinguang Pharmaceutical and Changyao Holdings followed suit.New Oriental acquired Taimei International Travel Service. Tianyancha App shows that recently, Taimei (Beijing) International Travel Service Co., Ltd. has undergone industrial and commercial changes, and Tianjin Vision Contemporary Technology Co., Ltd., the original wholly-owned shareholder, has withdrawn, and Beijing New Oriental Wokaide International Education Travel Co., Ltd. has been added as a shareholder and wholly owned. At the same time, the legal representative and several key personnel have changed. Taimei (Beijing) International Travel Service Co., Ltd. was established in May 2016. Its legal representative is Longhua with a registered capital of RMB 5 million. Its business scope covers domestic tourism business, inbound tourism business, outbound tourism business, exhibition activities, conference services, ticketing agents and air ticket sales agents.

The United States ITC issued a 337-part final ruling on electronic cigarette oil atomizers and their components and downstream products. According to China Trade Relief Information Network, on December 10th, the United States International Trade Commission (ITC) issued a notice saying that certain electronic cigarette oil atomizers and their components and downstream products (components thereof, And Products Containing the Same (investigation code: 337-TA-1392) made the final ruling of part 337: the preliminary ruling (No.32) made by the administrative judge in this case on November 8, 2024 was not reviewed, that is, the investigation of the following contents in this case was terminated based on the withdrawal of the applicant: U.S. registered patent No.11,369,757, paragraphs 2, 9 and 17. Complaints 23, 26 and 30 of U.S. Patent No.11,766,527 and complaints 11, 16-18 and 20 of U.S. Patent No.11,759,580.Ethereum hit $3,900/piece, up 1.81% in the day.BYD's legal department sued the blogger "Xu Lili Xll" and demanded compensation of 5 million yuan. BYD's legal department issued a statement saying that it was concerned that the online user "Xu Lili Xll" had made a lot of false statements against BYD and its sub-brands for a long time, which had caused serious damage to the company's brand reputation. In this regard, the company has fixed the evidence of relevant false statements, and decided to formally file a lawsuit against "Xu Lili Xll", demanding that it delete the infringing statements, eliminate the influence, and compensate RMB 5 million.

The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.The turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 15.6 billion yuan more than the previous day. Up to now, the turnover of Shanghai, Shenzhen and Beijing exceeded 1 trillion yuan, 15.6 billion yuan more than the previous day. Among them, the turnover of Shanghai Stock Exchange was 378.3 billion yuan, that of Shenzhen Stock Exchange was 611.9 billion yuan, and that of Beizheng 50 was 10.5 billion yuan.Wang Xiaochuan Baichuan Intelligent has set up a technology company in Ningbo with a number of AI businesses. According to enterprise investigation, recently, Ningbo Baichuan Ronghui Technology Co., Ltd. was established with Wang Xiaochuan as the legal representative and a registered capital of 70 million US dollars. Its business scope includes artificial intelligence dual-creation service platform, artificial intelligence theory and algorithm software development, artificial intelligence basic software development, artificial intelligence general application system, artificial intelligence public data platform and artificial intelligence public service platform technical consulting service. Equity penetration shows that the company is wholly owned by BAICHUAN AI (HK) LIMITED.